Childhood myopia: discover MiYOSMART iQ

Did you know that nearly one in three children in Canada has myopia between the ages of 11 and 13?¹ This visual condition is becoming increasingly common and can continue to progress throughout a child’s growth. 

Fortunately, solutions are now available that go beyond simply correcting vision. MiYOSMART® lenses are one example.

What Are MiYOSMART® Lenses?

MiYOSMART® is a range of lenses developed by HOYA to help manage the progression of myopia in children and teenagers. The patented D.I.M.S. (Defocus Incorporated Multiple Segments) technology integrated into MiYOSMART® lenses is based on several years of clinical research and has demonstrated its effectiveness in helping slow the progression of myopia in children.³⁻⁶

Today, MiYOSMART® is used in more than 50 countries and is supported by over 100 scientific publications.

An innovation that evolves with children’s needs

Building on several years of research and clinical experience, HOYA now introduces MiYOSMART® iQ, the latest evolution in its range of myopia-control lenses.² ¹⁰⁻¹²

This new generation incorporates D.I.M.S. T.E.D.™ (Triple Enhanced Design) technology, which enhances the already recognized D.I.M.S. technology.⁷⁻⁹

Specifically, this innovation includes:
•    an expanded treatment zone;
•    an increased level of defocus;
•    optimized positioning of the treatment zones closer to the centre of the lens.

These improvements were designed to act more effectively on certain areas of the retina involved in controlling myopia progression.⁷⁻⁹

Promising results for MiYOSMART iQ

Presented at the ARVO 2026 Annual Meeting, the first clinical results for MiYOSMART iQ are particularly encouraging.¹⁰⁻¹¹

After 12 months of wear:
•    9 out of 10 children showed no progression of their myopia;
•    researchers observed an average myopia progression close to zero;
•    eye growth remained minimal;
•    the visual performance observed was comparable to that offered by MiYOSMART® lenses.

MiYOSMART iQ is also the first HOYA lens whose clinical efficacy has been demonstrated in children as young as 4 years old.¹⁰⁻¹¹

Lenses designed for families’ everyday lives

Beyond myopia control, MiYOSMART iQ was designed to provide a comfortable and durable everyday experience.¹²

To learn more, we invite you to visit the MiYOSMART® product page.

Acting early can make all the difference

Early detection and appropriate management can help better control the progression of myopia during the growing years. To find out whether MiYOSMART® or MiYOSMART iQ lenses could be right for your child, ask your Opto-Réseau clinic.

Sources
¹ Canadian Institute for Health Information (CIHI). Canadian data on the prevalence of myopia in children aged 11 to 13.
² HOYA Vision Care. Internal data. MiYOSMART is supported by more than 100 scientific publications and is used in over 50 countries.
³ Lam CSY et al. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomized clinical trial. British Journal of Ophthalmology, 2020.
⁴ Lam CSY et al. Three-year clinical trial of DIMS spectacle lenses for myopia control. British Journal of Ophthalmology, 2022.
⁵ Lam CSY et al. Long-term myopia control effect and safety in children wearing DIMS spectacle lenses for 6 years. Scientific Reports, 2023.
⁶ Leung TW et al. Comparison of myopia progression in individuals wearing Defocus Incorporated Multiple Segments (DIMS) spectacle lenses for eight years versus shorter durations. BMJ Open Ophthalmology, 2026.
⁷ Smith III EL et al. Eccentricity-dependent effects of simultaneous competing defocus on emmetropization in infant rhesus monkeys. Vision Research, 2020.
⁸ Panorgias A et al. Retinal responses to simulated optical blur using a novel dead leaves ERG stimulus. Investigative Ophthalmology & Visual Science, 2021.
⁹ Swiatczak B et al. Retinal “sweet spot” for myopia treatment. Scientific Reports, 2024.
¹⁰ Tse DY et al. Myopia Control Efficacy of Defocus Incorporated Multiple Segments Spectacle Lens with Triple Enhanced Design: 12-month randomized controlled trial. ARVO 2026 Annual Meeting.
¹¹ HOYA. Internal data. Clinical results for the MiYOSMART iQ lens, 2026.
¹² HOYA. Internal data. Features and commercial data for the MiYOSMART iQ lens, 2026.